Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
The British Journal of Diabetes & Vascular Disease
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Bailey, C. J
Right arrow Articles by Day, C.
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Reviews

Review: Thiazolidinediones today

Clifford J Bailey

Diabetes Group, School of Pharmacy, Aston University, Birmingham B4 7ET, c.j.bailey{at}aston.ac.uk

Caroline Day

Diabetes Group, School of Pharmacy, Aston University, Birmingham B4 7ET

The thiazolidinediones (TZDs) rosiglitazone and pioglitazone are new oral antidiabetic agents with `insulin sensitising' activity for the treatment of type 2 diabetes. Rosiglitazone and pioglitazone produce a slowly generated antihyperglycaemic effect which is often accompanied by decreases in circulating insulin and free fatty acids. Circulating triglycerides may also decline, while low-density and high-density lipoprotein cholesterol concentrations are either unchanged or slightly increased, with little alteration to their ratio. The blood glucose-lowering efficacy of TZDs is typically additive or possibly more than additive to the effects of other classes of antidiabetic agents. In Europe rosiglitazone and pioglitazone can be used in combination with metformin or a sulphonylurea, whilst in the USA these TZDs can also be prescribed as monotherapy and pioglitazone in combination with insulin. Because TZDs tend to cause fluid retention they are excluded for patients with cardiac insufficiency. TZDs act via the nuclear peroxisome proliferator-activated receptor-gamma (PPAR{gamma}), which mediates the transcription of certain genes that are also responsive to insulin, enabling these agents to improve insulin action.

Key Words: thiazolidinediones • rosiglitazone • pioglitazone • antidiabetic agents • PPAR{gamma}

The British Journal of Diabetes & Vascular Disease, Vol. 1, No. 1, 7-13 (2001)
DOI: 10.1177/14746514010010010201
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 British Journal of Diabetes & Vascular DiseaseHome page
I. W Campbell
The role of metformin and pioglitazone in early combination treatment of type 2 diabetes mellitus
The British Journal of Diabetes & Vascular Disease, September 1, 2006; 6(5): 207 - 215.
[Abstract] [PDF]

Home page
 British Journal of Diabetes & Vascular DiseaseHome page
C. J Bailey, C. Day, and A. J Krentz
Nice timing for glitazones
The British Journal of Diabetes & Vascular Disease, September 1, 2003; 3(5): 366 - 367.
[Abstract] [PDF]